Contact:

RegeneRx:
Lori Smith
301.280.1992

RegeneRx Biopharmaceuticals, Inc. (AMEX: RGN) (www.regenerx.com) announced today that it is a major sponsor of “Walk a Mile in My Shoes Relay-Rally!”, the signature event of “National Epidermolysis Bullosa Awareness Week.” October 25th marks the first day of “National Epidermolysis Bullosa Awareness Week” as designated by United States Congress in honor of Americans with the genetic disease, Epidermolysis Bullosa (EB). People with EB are known as “butterflies” or “butterfly children” because their skin is as fragile as a butterfly’s wings. The “Walk a Mile in My Shoes Relay-Rally!” will begin in New York on October 25th and end in California on October 31st.

According to the event press release, “One ray of hope comes from major event sponsor, RegeneRx, which is doing Phase II clinical testing on Thymosin Beta 4, a multifaceted molecule that influences tissue and organ repair.” RegeneRx Biopharmaceuticals is testing its drug candidate in the most severely affected patients and the trial has been funded, in part, by the U.S. Food and Drug Administration.

For more information click on: http://www.prweb.com/releases/2007/10/prweb563020.htm.

About Epidermolysis Bullosa
EB is a group of genetic disorders characterized by exceptionally fragile skin and chronic, painful wounds and blisters caused by the slightest trauma, even normal day-to-day activities. This circumstance is caused by a missing or damaged protein that causes a breakdown between skin layers, resulting in skin that can slip off as easily as that of a ripe peach. The disease affects people of both genders and every ethnicity. It is believed that as many as 500,000 people worldwide suffer from one of the forms of EB, and carriers of the mutated gene are more prevalent than one might guess. It is an “orphan disorder,” meaning the condition itself affects less than 200,000 Americans.

Common occurrences in severe forms of EB include open wounds, disfiguring scars, musculoskeletal deformities causing restricted function, internal and external blistering, malnutrition, and deterioration of the eyes and teeth. It is often disabling and life-threatening, requiring daily wound care similar to that given to acute burn patients. Checking wounds for infection is a necessity, so baths and bandaging are a daily occurrence - an ordeal that is often so excruciating that it requires strong pain medication.

About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43 amino acid peptide, in part, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore, RegeneRx is developing TB4 as the cornerstone of its therapeutic platform. The technology platform has many potential applications in both the pharmaceutical and consumer products sectors. RegeneRx holds nearly 60 world-wide patents and patent applications related to dermal, ophthalmic, and internal wounds and tissue repair, cardiac and neurological injuries, septic shock and several consumer product areas. RegeneRx is currently sponsoring three Phase II chronic dermal wound healing clinical trials, a Phase II ophthalmic trial, and a Phase I clinical trial to assess the safety of its cardiovascular drug formulation as part of its ongoing clinical development program.

The RegeneRx Technology Platform
TB4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class drug candidate that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation. One of TB4’s key mechanisms of action is its ability to regulate the cell-building protein, actin, a vital component of cell structure and movement. Of the thousands of proteins in cells, actin represents up to 10% of the total protein and, thus, plays a major role in the physiology of the cell. RegeneRx has identified several molecular variations of TB4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health, and at other academic institutions throughout the U.S., have published numerous scientific articles indicating that TB4 is effective in accelerating dermal and corneal wound healing in several animal models, under a variety of conditions. In two articles published in the scientific journal, Nature, researchers found that TB4 protects heart tissue following a myocardial infarction and can regenerate coronary vessels in laboratory animals. Abstracts of scientific papers related to TB4’s mechanisms of action may be viewed at RegeneRx’s web page: www.regenerx.com.

Safe Harbor Statement
The information in this press release may include certain forward-looking statements, including without limitation statements such as “believe,” “estimate,” “expect,” and “target,” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company’s current expectations regarding future events, including the ongoing and prospective development of TB4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements are subject to risks and uncertainties, including those reflected in the Company’s filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-K. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.

Back To 2007 Press Release Archives